发明名称 |
Quinoline derivatives for use in the treatment or prevention of viral infection |
摘要 |
The present invention relates to A quinoline derivative of formula (I)
or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites,
for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain. |
申请公布号 |
EP3058940(A1) |
申请公布日期 |
2016.08.24 |
申请号 |
EP20150305277 |
申请日期 |
2015.02.23 |
申请人 |
ABIVAX;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;INSTITUT CURIE;UNIVERSITÉ MONTPELLIER |
发明人 |
SCHERRER, DIDIER;GARCEL, AUDE;CAMPOS, NOELIE;TAZI, JAMAL;VAUTRIN, AUDREY;MAHUTEAU-BETZER, FLORENCE;NAJMAN, ROMAIN;FORNARELLI, PAULINE |
分类号 |
A61K31/4709;A61P31/18 |
主分类号 |
A61K31/4709 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|